- Trial phase
- Approved
- Time to market
- Already approved and marketed in the US (since January 2022) and EU. Patent protection extends to approximately January 2036 per DrugPatentWatch.
- Why 3/10
- Cibinqo is already approved and commercialized with no pending PDUFA date or pivotal readout in the next ~12 months. It is one of many products within Pfizer's $62B+ revenue base, so even a major label expansion would have a modest impact on the stock. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Cibinqo is an approved, marketed drug with no near-term binary catalysts. Watch for any announcement of a regulatory submission for chronic hand eczema (Phase 2 data was positive in 2026) and for quarterly sales trends within Pfizer's broader earnings reports. The drug's impact on PFE shares will remain modest given Pfizer's size and diversification.
Price Chart
Executive Summary
Cibinqo (abrocitinib) is Pfizer's oral JAK1 inhibitor for moderate-to-severe atopic dermatitis, approved by the FDA in January 2022 for adults and expanded to adolescents in 2023. It competes in a crowded market against injectable biologics (dupilumab, tralokinumab) and oral JAK inhibitors (upadacitinib). The drug carries a boxed warning for serious infections, malignancy, and cardiovascular events common to the JAK inhibitor class. Positive Phase 2 data for chronic hand eczema was presented in 2026, but no regulatory submission has been announced. As an already-marketed product within Pfizer's massive diversified portfolio, Cibinqo is not a standalone binary catalyst for the stock.
How It Works
Cibinqo is a once-daily oral pill that blocks Janus kinase 1 (JAK1), an enzyme inside immune cells that drives inflammation. By inhibiting JAK1, the drug reduces the inflammatory signals that cause the redness, itching and skin damage in eczema (atopic dermatitis).
Trial Status
Cibinqo was FDA-approved in January 2022 for adults with moderate-to-severe atopic dermatitis, and expanded to adolescents (12-17 years) in February 2023. The JADE clinical program included multiple Phase 3 trials. A Phase 2 trial for chronic hand eczema (NCT06283550) completed in 2026 with positive results presented at AAD 2026. Long-term extension data (JADE EXTEND) out to 112 weeks has been published.
The Two-Sided Case
Upcoming Catalysts
- No hard binary catalysts (PDUFA or pivotal readout) are scheduled in the next ~12 months. The Phase 2 chronic hand eczema data may support a future label expansion filing, but no submission has been announced.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report